24

September

University of Minnesota discovery is now a first-in-human clinical trial for leukemia

MINNEAPOLIS, MN- September 19, 2019 -The discovery of tri-specific natural killer engagers (TriKE™), a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially, has led to a new Phase I, first-in-human study to treat leukemia. The study is opening exclusively at the University of Minnesota Medical Center, and is being sponsored by GT Biopharma, Inc. Read More
Victoria

Victoria has blogged 600 posts